Treatment of Hemodialyzed Patients with Sunitinib in Renal Cell Carcinoma

Publisher： Karger

E-ISSN： 1421-9794|56|6|485-491

ISSN： 0009-3157

Source： Chemotherapy, Vol.56, Iss.6, 2010-11, pp. : 485-491

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Comparative Efficacy of Sunitinib versus Sorafenib as First-Line Treatment for Patients with Metastatic Renal Cell Carcinoma

By  

Chemotherapy, Vol. 58, Iss. 6, 2013-03 ,pp. : 468-474

Karger

Access to resources Recommend Favorite

Effects and Side Effects of Using Sorafenib and Sunitinib in the Treatment of Metastatic Renal Cell Carcinoma

By Randrup Hansen Caroline   Grimm Daniela   Bauer Johann   Wehland Markus   Magnusson Nils E.  

International Journal of Molecular Sciences, Vol. 18, Iss. 2, 2017-02 ,pp. : 461-461

MDPI

Access to resources Recommend Favorite

Does Sunitinib-Induced Hypothyroidism Play a Role in the Activity of Sunitinib in Metastatic Renal Cell Carcinoma?

By  

Chemotherapy, Vol. 58, Iss. 3, 2012-06 ,pp. : 200-205

Karger

Access to resources Recommend Favorite

Sunitinib-Induced Autoimmune Thyroiditis in a Patient with Metastatic Renal Cell Carcinoma: A Case Report

By  

Chemotherapy, Vol. 58, Iss. 2, 2012-05 ,pp. : 142-145

Karger

Access to resources Recommend Favorite

Hypertension Caused by Lenvatinib and Everolimus in the Treatment of Metastatic Renal Cell Carcinoma

By Bendtsen Mathias Alrø Fichtner   Grimm Daniela   Bauer Johann   Wehland Markus   Wise Petra   Magnusson Nils E.   Infanger Manfred   Krüger Marcus  

International Journal of Molecular Sciences, Vol. 18, Iss. 8, 2017-08 ,pp. : 1736-1736

MDPI

Access to resources Recommend Favorite